ASRT vs DBVT vs PRGO vs SLRX vs IMVT

For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.

8% revenue growth year-over-year, versus -5. 0% for Assertio Holdings, Inc. (ASRT). Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Assertio Holdings, Inc.

(ASRT) delivered a total return of +881. 1%, compared to -100. 0% for Salarius Pharmaceuticals, Inc. (SLRX). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus SLRX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Assertio Holdings, Inc.

(ASRT) is the lower-risk stock at 0. 72β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 90% more volatile than ASRT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.

8% versus -5. 0% for Assertio Holdings, Inc. (ASRT). On earnings-per-share growth, the picture is similar: Assertio Holdings, Inc. grew EPS -37. 4% year-over-year, compared to -1522. 7% for Salarius Pharmaceuticals, Inc.. Over a 3-year CAGR, PRGO leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DBV Technologies S.

A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -18. 1% for ASRT. At the gross margin level — before operating expenses — ASRT leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

In this comparison, PRGO (9.

8% yield) pays a dividend. ASRT, DBVT, SLRX, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

18), 9. 8% yield). Both have compounded well over 10 years (PRGO: -77. 7%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ASRT is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; PRGO is a small-cap income-oriented stock; SLRX is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock. PRGO pays a dividend while ASRT, DBVT, SLRX, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.